G3139 is a phosphorothioate oligodeoxyribonucleotide that is targeted to the initiation codon region of the Bcl-2 mRNA, which downregulates Bcl-2 protein and mRNA expression via an antisense mechanism. In previous work, we have demonstrated that the phenotype observed in several prostate and melanoma cell lines after treatment with G3139 appears to be Bcl-2 independent. In contrast, downregulation of Bcl-2 expression by a small interfering RNA (siRNA) produced little or no phenotype change. In the present work, we performed an Agilent oligonucleotide microarray assay on mRNA isolated from PC3 prostate cancer cells that were treated with two different oligonucleotide gene-silencing reagents. G3139 and a Bcl-2-targeting siRNA both downregulate Bcl-2 expression, but via different mechanisms. A side-by-side comparative analysis showed that the expression profile generated by these molecules differs substantially. The study revealed upregulation of the expression of stress-inducible genes in PC3 cells at 1 and 3 days after a 5-h transfection with G3139 complexed with Lipofectamine 2000. In contrast, only a very diminished stress response was seen 1 and 3 days after a 24-h transfection of siRNA/ Lipofectamine 2000 complexes. These results highlight the profound differences in off-target effects in cells treated with the phosphorothioate oligonucleotide G3139 and with an siRNA targeted to the same gene, and provide further evidence that the mechanism of action of G3139 is not related to Bcl-2 silencing.
Introduction
The Bcl-2 gene is a negative regulator of cellular apoptosis that displays heightened expression in a wide range of cancers. Increased levels of this and other apoptotic suppressors (e.g., inhibitors of apoptosis (IAPs)) augment cellular resilience toward external stress and are suspected to be an origin of drug resistance against chemotherapeutic agents designed to induce programmed cell death. [1] [2] [3] [4] [5] G3139 is a phosphorothioate-modified antisense oligodeoxynucleotide (PS-ODN) that targets the initiation codon of the Bcl-2 mRNA. While preclinical studies revealed that G3139 induced a robust apoptotic/cytostatic phenotype in LNCaP and PC3 cells, respectively, small interfering RNA (siRNA) targeting the Bcl2 transcript failed to generate similar outcomes. 6 This finding brings into question the mechanism of action of G3139 (and possibly related PS-ODNs), suggesting that knockdown of Bcl-2 alone is unrelated to or insufficient to explain the cell culture phenotypes.
A strong correlation between small-molecule treatment and target modulation is essential in therapeutic drug development, and inconsistencies between predicted and experimental outcomes are often indicative of deficiencies in the understanding of a reagent's mode of action. In the following study, we provide an example of how two techniques, RNAi-mediated gene knockdown and gene expression profiling, can be combined to investigate the underlying mechanism of drug action. Specifically, a sideby-side comparative analysis of G3139 and siRNA-based gene knockdown was performed using microarray gene profiling. The results of these studies show that, while both siRNA and G3139 efficiently target Bcl-2 transcripts for degradation, the expression profile generated by the two Bcl2-targeting reagents are widely disparate. This study provides insights into the possible mechanism of G3139 action and describes a valuable approach for evaluating prospective therapeutic agents.
Materials and methods
Cell culture PC3 and LNCaP prostate cancer cells were obtained from the American Type Culture Collection (Rockville, MD) and grown in RPMI (Invitrogen, Grand Island, NY) plus 10% FBS, containing 10% (v/v) heat inactivated (561C) fetal bovine serum supplemented with 1% nonessential amino acids, 1% pyruvate, 25 mM HEPES, 100 U/ml penicillin G sodium and 100 mg/ml streptomycin sulfate. Stock cultures were maintained at 371C in a humidified 5% CO 2 incubator.
Microarray analysis
Total RNA was isolated using the RNeasy kit with oncolumn DNase digestion (Qiagen, Valencia, CA) and assessed for integrity using an RNA Nanochip 6000 and Agilent's Bioanalyzer. Purified total RNA was amplified and Cy3-or Cy5-labeled (Perkin-Elmer) using Agilent's Low Input RNA Fluorescent Linear Amplification Kit. Hybridizations were performed on Agilent's Human 1A(V2) Oligo Microarrays (http://www.agilent.com). The hybridization reference (Cy3) used in these studies was untransfected cells. Slides were washed and dried using 6 Â and 0.06 Â SSPE with 0.025% N-lauroylsarcosine and Agilent's nonaqueous drying and stabilization solution. Arrays were scanned on an Agilent Microarray Scanner (model G2505B) and raw images were processed using Feature Extraction (v. 7.5.1) software. Further analysis was conducted using Spotfire Decision Site 8.0 and the Spotfire Functional Genomics Module. Data were filtered by outlier flag status (feature and background outlier flags and the well above background signal cutoff). A two-fold cutoff (LogRatio of 40.3 or oÀ0.3) was applied to genes used in comparative analysis. To identify the gene list in Table 1 , genes that were upregulated by two-fold or more in G3139-treated samples, but none of the siRNA or control samples, were selected.
Reagents
The anti-Bcl-2 monoclonal antibody used in Western blot analysis was purchased from Dako (Carpinteria, CA). The anti-tubulin monoclonal antibody was acquired from Sigma-Aldrich (St Louis, MO) and Lipofectamine 2000 was purchased from Invitrogen. Phosphorothioate-(G3139) and control phosphodiester-(G3139 PO ) containing oligonucleotides having the sequence: 5 0 -dTCTC CCAGCGTGCGCCAT differ only in the type of internucleotide linkage. These molecules, as well as an additional antisense control, G3139 mm , containing two mismatches with respect to G3139 (5 0 -dTCTCCCAGCATGTGCCAT) were kindly supplied by Genta (Berkeley Heights, NJ). All siRNAs were synthesized by Dharmacon (Lafayette, CO) using 2 0 ACE chemistry. Oligonucleotide transfections Cells were seeded in complete media (without antibiotics) the day before the experiment (10-cm dishes, 1-1.2 Â 10 6 cells per dish). The concentration of antisense molecules for all the experiments was either 50 or 100 nM. All procedures were performed in Opti-MEM medium (Gibco BRL) and the transfection incubation time for oligonucleotide/Lipofectamine 2000 complexes was 5 h. The total incubation time before cell lysis and protein isolation was 24, 48 or 72 h. siRNA transfections Cells were seeded in complete media in 10-cm dishes (1-1.2 Â 10 6. cells per dish) the day before the experiment. For all assays, the concentration of siRNAs during transfection was 10 nM. All transfections were performed in a mixture of Opti-MEM and complete media without antibiotics, as described previously. 6 The transfection incubation time for siRNA/Lipofectamine 2000 complexes was 24 h. The total incubation time before cell lysis and protein isolation was 72 h.
Isolation of RNA and RT-PCR Total RNA was isolated from PC3 and LNCaP cells using QIAGEN's RNeasy kit (Qiagen, Valencia, CA). RNA was reverse-transcribed using RT-PCR reactions based on the Super-Script TM One-Step RT-PCR with Platinum R Taq (Invitrogen). All RT-PCR reactions were performed with Bcl-2 and b-actin primers as described previously.
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The Bcl-2 and b-actin amplicons were 459 and 246 bp, respectively. The RT-PCR products were resolved on 1% agarose gels and visualized by ethidium bromide staining.
Western blot analysis
All Western blots were performed as described previously, 6 and quantitated by laser-scanning densitometry.
Determination of rate of cell proliferation
The rate of proliferation of PC3 cells was determined using an MTT assay, as described previously. 7 Experiments were performed in quadruplicate, and data are presented as the average7s.d.
Apoptosis assay
Cells treated for 72 h with oligonucleotides were harvested following trypsinization, and apoptotic cells were assayed by FACS using an Annexin V-FITC apoptosis detection kit. 6 Early apoptotic cells were defined as those that bound to Annexin V-FITC, but excluded propidium iodide (PI). Cells in late apoptotic stages were labeled with both Annexin V-FITC and PI.
Results
Both G3139 and the Bcl-2 1 and Bcl-2 2 siRNAs target Bcl-2 for gene knockdown It has been previously demonstrated that the antisense molecule G3139 is a potent Bcl-2 knockdown reagent. siRNAs that utilize the recently discovered RNAi pathway to effect transcript degradation have also been identified as valuable tools to elucidate gene function and pathway analysis. In order to test the linkage between Bcl-2 knockdown and previously associated G3139-induced phenotypes (e.g. cytostasis/apoptosis), two additional Bcl-2 knockdown reagents (siRNA Bcl2-1 and siRNA Bcl2-2 ) were identified using the advanced siRNA rational design algorithm developed by Reynolds et al. siRNA Bcl2-1 and siRNA Bcl2-2 proved to be more potent silencing reagents than G3139 in both cell types, suppressing expression in PC3 and LNCaP populations at lower concentrations (10 nM) by as much as 80-90%, 1 day post-transfection. As equivalent levels of transcript knockdown were observed by quantitative RT-PCR (Figure 1c ), the mode of action of both molecules (antisense and siRNA) was assumed to involve transcript degradation. As both Bcl-2-targeting siRNA and G3139 generate near-equivalent knockdown of the Bcl-2 protein, it would be expected that both the antisense and siRNA molecules should induce equivalent phenotypes.
G3139 and siRNA
Bcl2-1 induce disparate phenotypes in PC3 and LNCaP cells Previous studies have demonstrated that G3139 induces apoptosis and cytostasis in LNCaP 9 and PC3 cells, 7, 10 respectively. To study the equivalency of G3139-and Bcl-2-targeting siRNAs as apoptotic/cytostatic agents, cultures of LNCaP or PC3 cells were transfected with the appropriate molecule and the apoptotic state and growth rate were monitored using Annexin V (Figure 2a ) and MTT assays (Figures 2b and c) , respectively. Surprisingly, neither of the Bcl-2-targeting siRNAs (siRNA Bcl2-1 or siRNA Bcl2-2 ) nor the nontargeting siRNA controls generated phenotypes equivalent to G3139 in either cell line ( Figure 2 ). In LNCaP (3 days post-transfection), G3139 induced apoptosis in nearly half of the population (46.8%; Supplementary Figure 1) . In contrast, the fraction of LNCaP cells that entered apoptosis upon transfection with siRNA Bcl2-1 is small and closely parallels that observed in untreated control populations (13.1% for untreated cells, 18.6 and 15.8% for siRNA cont-3 and siRNA Bcl2-1 -treated cultures, respectively). Similarly, G3139 and siRNA Bcl2-1 induce distinctly different phenotypes in PC3 cells. Transfection with 50 nM G3139 induced a sharp decline in the culture doubling time over the course of the 5-day experiment (Figure 2b ). In contrast, transfection with 100 nM siRNA Bcl2-1 (or siRNA cont-2 ) induced little or no changes in the cell proliferation profile (Figure 2c ). Similar observations were made with PC3 cells transfected with siRNA (data not shown). Thus, while both G3139-and Bcl-2-targeting siRNAs strongly downregulate Bcl-2 expression, the effects of these two classes of molecules on cell proliferation and apoptosis are distinct, suggesting that the mechanism of action of G3139 is not exclusively the result of its action on Bcl-2.
Comparative expression analysis of G3139-and siRNA Bcl2-1 -treated PC3 cells Preliminary gene expression studies in G3139-and siRNA Bcl2-1 -treated LNCaP cells showed this cell line to be hypersensitive to lipid treatment alone (B3000 genes modulated by greater than two-fold in cells treated with Lipofectamine 2000). LNCaP cells treated with G3139 undergo cellular apoptosis rather than cytostasis, and the Lipofectamine 2000 is more toxic to these cells than to PC3 cells. ) was Cy5-labeled and co-hybridized to Agilent's Human 1A (V2) chips along with a Cy3-labeled reference RNA population derived from untreated cells.
On the basis of the Agilent oligonucleotide array data (Figure 3) , after 1 day, lipid-mediated delivery of G3139, and to a much lesser extent G3139 mm , upregulates a set of genes that are not upregulated by the anti-Bcl-2 siRNA. The pattern of gene expression observed with this siRNA clusters with that seen with the control siRNA, and with lipid treatment alone. The signature induced by a phosphodiester congener of G3139, G3139 PO , clusters with Lipofectamine 2000 alone when employed at concentrations used for the oligonucleotide transfection. However, the amount of internalized G3139 PO as a function of time is usually significantly less than the amount of internalized phosphorothioate G3139, and any comparison between the two must take account of this difference, which may be due to digestion of the G3139 PO and exocytosis of the products.
Consistent with the 1-day time point, by 3 days after the transfection, hierarchical clustering analysis demonstrates that the G3139-induced gene expression profile markedly deviates from all other 3-day profiles. The patterns induced by functional Bcl-2 targeting siRNA Bcl2-1 mimic closely siRNA cont-1 and the G3139 PO control patterns derived from PC3 cells treated with either the Bcl2-2 or NS4 siRNAs, or the G3139 PO oligonucleotide are similar. To a lesser extent, the gene expression profile pattern derived from Lipofectamine 2000 alone (at a concentration of 1.0 mg/ml, which is the concentration used to delivery the oligodeoxyribonucleotides) and G3139 mm /Lipofectamine 2000 also cluster with these gene profiles. In contrast, the 3-day gene expression profile of PC3 cells treated with G3139 (50 nM)/Lipofectamine 2000 (1 mg/ml) markedly deviates from this pattern, and does not cluster with any of the other 3-day profiles. Rather, the unique gene profile pattern produced by G3139 after 1 day is also observed at 3 days, with additional unique clusters of genes affected.
The upregulated expression of additional stress-inducible genes (G1P3, IFI44, STAT1, MX2, IFIT1, OASL and IFIT4) has been seen previously in G3139-treated PC3 cells, 10 and is also observed here. The upregulation of stress-inducible genes, similar to what was previously found, was induced at 3 days to a much lesser extent by either controls (Lipofectamine 2000 þ G3139 mm or þ G3139 PO ) than with G3139. Neither the siRNA control nor the siRNA Bcl-2 induced a stress response at either 1 or 3 days in a parallel experiment (with the exception of IFITM1 expression). It is worth mentioning that the expression of two stress-related, interferon-b or -ginducible genes (MX1 and IFITM1) tends to be upregulated to some extent in both PC3 and HeLa cells by Lipofectamine 2000 alone at 1.3 mg/ml (E Anderson, unpublished data). The induction of a stress response by Lipofectamine 2000 alone has not hitherto been, we believe, well appreciated.
Upregulation of the expression of many stress-related genes by G3139 was much more pronounced after 3 days compared to the 1-day time point. Previously, we demonstrated that upregulation of the expression of these genes can be seen after 1 day 10 when more invasive delivery methods were used (Lipofectin with G3139 at a 400 nM concentration). This once again indicates the importance of formulation in the induction and extent of the G3139-induced phenotype. In this context, it should be noted that the 30% increase in Lipofectamine 2000 concentration (from 1.0 to 1.3 mg/ml) used in the oligodeoxyribonucleotide (i.e., G3139, G3139 mm and G3139 PO ) and siRNA transfections, respectively, was sufficient to differentially upregulate the expression of the IFIT4 stress response gene.
A set of genes uniquely upregulated by G3139 in PC3 cells at 1 and 3 days after the transfection is presented in Table 1 . However, for most genes the fold upregulation at 3 days is only slightly above the arbitrary two-fold cutoff, and thus their significance is uncertain.
A set of genes downregulated by G3139 in PC3 cells at 1 or 3 days after the transfection is presented in Table 2 . Similar to the observation for upregulated genes, on these days only minimal downregulation of uncertain significance was observed. Only four genes exceeded the arbitrary two-fold cutoff at both time points (ACTR1A, CTNNBL1, BC030623 and DNM2).
In summary, a heatmap of the clustered data collected from cell populations at 1 and 3 days after transfection identified drastically different responses to the two Bcl-2 knockdown reagents (Figure 3) . In addition to a lipidspecific, downregulation signature that is associated with the higher concentrations and/or exposure times of Lipofectamine 2000 used in antisense transfection (Lipid signature), G3139-treated PC3 cells show a dramatic increase in the expression of a wide range of genes at the 24-h time point. This signature is absent in all of the relevant controls (lipid-only treatment, siRNA cont-1 , G3139 PO , and G3139 mm ) as well as siRNA Bcl2-1 -treated samples.
On day 3, the G3139 upregulation signature is expanded and includes additional lipid-related components. Still, a G3139-specific expression pattern is distinct from that observed in any of the other samples. The identities of the genes that are uniquely upregulated by more than two-fold by G3139 at both the 24-and 72-h time points are listed in Table 1 , and, interestingly, include several genes involved in the regulation of cell proliferation (e.g. RASSF1, JUNB, ARHE/RND3, MAD and DMTF1). Furthermore, an attempt to identify genes that were commonly up-or downregulated by both G3139 and siRNA Bcl2-1 -treated samples (but not associated controls) failed to identify any subsets of similarly modulated genes (aside from Bcl-2). Thus, while the G3139-and siRNA Bcl2-1 -treated populations exhibited similar levels of Bcl-2 knockdown, the similarities in the expression profiles fail to extend beyond the primary target. For this reason, we believe that it is highly unlikely that Bcl-2 knockdown is the major mechanism of G3139 action. Gene
Discussion
Parallel and complementary experimental approaches are often needed to obtain a high degree of confidence that a phenotype induced by any small molecule is associated with modulation of target gene function. In yeast and other model organisms, this can often be achieved by comparing the phenotype observed in drug-treated cells with that of artificial mutants that have partial (hypomorphs) or complete (null) deficiencies in target gene function. While gene knockouts can provide the necessary controls in more advanced organisms (e.g. mice knockouts), prohibitive costs or embryonic lethality frequently make this approach problematic.
The use of gene expression analysis to assess the mode of action of multiple drug candidates is not novel. Owa et al. 11 explored the relationship between small-molecule structure, drug sensitivity pathways and gene expression in a library of sulfonamide-based molecules having antitumor activities. In the present study, we have modified this technique by adding an internal control (siRNA targeted knockdown) that allows further delineation of target-related and -unrelated phenotypes. Studies of G3139 and a Bcl-2-targeting siRNA showed the near equivalency of these two reagents as Bcl-2-targeting molecules. siRNA use the recently identified RNAi pathway to target gene knockdown by transcript degradation. These duplexes are relatively sequence specific and can induce gene knockdown at low nanomolar concentrations. In contrast, the phosphorothioate oligonucleotide G3139 acts via a less-well characterized antisense mechanism, and requires significantly higher concentrations and times to effect equivalent levels of Bcl-2 modulation. Surprisingly, while both G3139 and siR-NA Bcl2-1 induce similar levels of Bcl-2 knockdown, the phenotypes generated in cultured cells are distinctly different. In LNCaP and PC3 cells, G3139 induces apoptosis and cytostasis, respectively. These responses are undetected in siRNA Bcl2-1 -treated cells, suggesting that targeting Bcl-2 alone is insufficient (or unrelated) to the observed phenotypes.
While lipid-transfected LNCaP cells were found to be intractable to expression analysis, possible clues as to the origins of the cytostatic phenotype observed in G3139-treated PC3 cells are found in the gene expression profiles. PC3 cells treated with G3139 exhibit a strong upregulation signature that begins within 24 h of transfection and is preserved for at least 3 days. As this signature is: (1) unique to the modified antisense and is absent in all relevant controls (e.g. G3139 PO , G3139 mm , lipid-treated cells, siRNA Bcl2-1 -treated cells), and (2) correlates with the timing of the observed cytostatic phenotype, we hypothesize that the G3139-induced phenotype is either Bcl-2-independent or the result of Bcl-2 knockdown in conjunction with the upregulation of other genes. While we are cautious in speculating on the identity of genes that could play a role in the observed cytostasis, the G3139 upregulation signature present on days 1 and 3 provides several provocative candidates. RASSF1 belongs to a small family of growth-inhibitory proteins (including Nore1, RASSF2, RASS3 and others) that have been shown to induce cell cycle arrest, 12 and MAD belongs to a family of transcriptional repressors that act in conjunction with Max to inhibit Myc-directed cell growth and differentiation. 13 Upregulation of these two genes, as well as DMTF1 (a cyclin D-binding Myb-like protein, that induces growth arrest 14 and ARHE/RND3 (an inhibitor of Rho function), suggest lead candidates that either separately or in conjunction with Bcl-2 knockdown could explain the G3139-induced phenotype in PC3 cells. Similarly, downregulation of CTNNBL1 (catenin, betalike 1), a protein whose C-terminus is proapoptotic, 15 may also help to explain why apoptosis in these cells is suppressed after G3139 treatment. In addition, some of the off-target effects observed in G3139-treated PC3 cells may be due to the presence of a bis-CpG motif in G3139, 7 which is absent in G3139 mm . However, these effects are unrelated to 'classical' immune cell-related CpG effects, 16 as PC3 cells do not express TLR9. 10 In summary, the work described above addresses the relevance (or lack thereof) of Bcl-2 as a potential therapeutic target. In addition, we describe a new approach that combines RNAi and gene expression profiling, which can be used to assess the validity of a given gene product as a therapeutic target. Application of this methodology to future pre-clinical studies may enable researchers to better discriminate the value of various small-molecule drug candidates and enhance/modify treatment regimes used in clinical trials.
